Display options
Cite
Lane JD, Tinker A. Have the Findings from Clinical Risk Prediction and Trials Any Key Messages for Safety Pharmacology?. Front Physiol. 2017;8:890doi: 10.3389/fphys.2017.00890.
Lane, J. D., & Tinker, A. (2017). Have the Findings from Clinical Risk Prediction and Trials Any Key Messages for Safety Pharmacology?. Frontiers in physiology, 8890. https://doi.org/10.3389/fphys.2017.00890
Lane, Jem D, and Tinker, Andrew. "Have the Findings from Clinical Risk Prediction and Trials Any Key Messages for Safety Pharmacology?." Frontiers in physiology vol. 8 (2017): 890. doi: https://doi.org/10.3389/fphys.2017.00890
Lane JD, Tinker A. Have the Findings from Clinical Risk Prediction and Trials Any Key Messages for Safety Pharmacology?. Front Physiol. 2017 Nov 06;8:890. doi: 10.3389/fphys.2017.00890. eCollection 2017. PMID: 29163223; PMCID: PMC5681497.
Copy Download .nbib Format: NLM
Share it on

Front Physiol. 2017 Nov 06;8:890. doi: 10.3389/fphys.2017.00890. eCollection 2017.

Have the Findings from Clinical Risk Prediction and Trials Any Key Messages for Safety Pharmacology?.

Frontiers in physiology

Jem D Lane, Andrew Tinker

Affiliations

  1. William Harvey Heart Centre, Barts and The London School of Medicine and Dentistry, London, United Kingdom.
  2. Department of Cardiac Electrophysiology, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom.

PMID: 29163223 PMCID: PMC5681497 DOI: 10.3389/fphys.2017.00890

Abstract

Anti-arrhythmic drugs are a mainstay in the management of symptoms related to arrhythmias, and are adjuncts in prevention and treatment of life-threatening ventricular arrhythmias. However, they also have the potential for pro-arrhythmia and thus the prediction of arrhythmia predisposition and drug response are critical issues. Clinical trials are the latter stages in the safety testing and efficacy process prior to market release, and as such serve as a critical safeguard. In this review, we look at some of the lessons to be learned from approaches to arrhythmia prediction in patients, clinical trials of drugs used in the treatment of arrhythmias, and the implications for the design of pre-clinical safety pharmacology testing.

Keywords: anti-arrhythmia agents; arrhythmias; cardiac; cardiac ion channels; long QT; torsades de pointes

References

  1. J Am Coll Cardiol. 2012 Aug 28;60(9):841-50 - PubMed
  2. Nat Rev Drug Discov. 2006 Dec;5(12):1034-49 - PubMed
  3. J Cardiovasc Electrophysiol. 2006 Mar;17(3):337-40 - PubMed
  4. Mol Pharmacol. 1995 Feb;47(2):322-9 - PubMed
  5. N Engl J Med. 1989 Aug 10;321(6):386-8 - PubMed
  6. N Engl J Med. 1989 Aug 10;321(6):406-12 - PubMed
  7. N Engl J Med. 2005 May 5;352(18):1861-72 - PubMed
  8. Europace. 2011 Feb;13(2):161-73 - PubMed
  9. J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605 - PubMed
  10. Trends Cardiovasc Med. 2004 Feb;14(2):61-6 - PubMed
  11. Br J Pharmacol. 2008 Aug;154(7):1457-64 - PubMed
  12. Circ Arrhythm Electrophysiol. 2009 Apr;2(2):185-94 - PubMed
  13. Ann Intern Med. 1997 Sep 15;127(6):417-22 - PubMed
  14. Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):E2098-105 - PubMed
  15. Lancet. 1994 Aug 20;344(8921):493-8 - PubMed
  16. JAMA. 2006 Jan 11;295(2):165-71 - PubMed
  17. Circ Arrhythm Electrophysiol. 2015 Aug;8(4):772-6 - PubMed
  18. Circulation. 1995 Oct 1;92(7):1954-68 - PubMed
  19. Eur Heart J. 2009 May;30(10):1245-53 - PubMed
  20. Heart Rhythm. 2011 Nov;8(11):1756-7 - PubMed
  21. J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:21-36 - PubMed
  22. N Engl J Med. 2005 Jan 20;352(3):225-37 - PubMed
  23. Front Physiol. 2017 Aug 18;8:597 - PubMed
  24. Curr Pharmacol Rep. 2016;2(6):339-344 - PubMed
  25. Circulation. 2009 Mar 17;119(10):e241-50 - PubMed
  26. Circulation. 2017 Apr 4;135(14 ):1300-1310 - PubMed
  27. Card Electrophysiol Clin. 2016 Jun;8(2):453-65 - PubMed
  28. Pharmacol Rev. 1999 Dec;51(4):651-90 - PubMed
  29. Mayo Clin Proc. 2013 Apr;88(4):315-25 - PubMed
  30. Lancet. 2012 May 19;379(9829):1922 - PubMed
  31. Circ Arrhythm Electrophysiol. 2010 Aug;3(4):391-400 - PubMed
  32. N Engl J Med. 1991 Mar 21;324(12):781-8 - PubMed
  33. N Engl J Med. 2008 Jun 19;358(25):2678-87 - PubMed
  34. N Engl J Med. 1996 May 23;334(21):1349-55 - PubMed
  35. Nucleic Acids Res. 2016 Jan 4;44(D1):D1080-6 - PubMed
  36. J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):6-11 - PubMed
  37. Circulation. 2005 Oct 18;112(16):2517-29 - PubMed
  38. Physiol Rev. 2005 Oct;85(4):1205-53 - PubMed
  39. N Engl J Med. 2004 Mar 4;350(10):1013-22 - PubMed
  40. Europace. 2016 Sep;18(9):1287-98 - PubMed
  41. Am Heart J. 2014 Mar;167(3):292-300 - PubMed
  42. J Am Coll Cardiol. 2016 Apr 5;67(13):1639-1650 - PubMed
  43. Circ Res. 1999 Apr 16;84(7):776-84 - PubMed
  44. Am J Cardiol. 1997 Nov 13;80(9B):35J-39J - PubMed
  45. J Am Coll Cardiol. 1997 Sep;30(3):791-8 - PubMed
  46. Eur Heart J. 2017 Jul 14;38(27):2110-2118 - PubMed
  47. Ann Intern Med. 1989 Jul 15;111(2):107-11 - PubMed
  48. Heart Rhythm. 2014 Oct;11(10):e166-96 - PubMed
  49. Nat Genet. 2014 Aug;46(8):826-36 - PubMed
  50. N Engl J Med. 2009 Feb 12;360(7):668-78 - PubMed
  51. Physiol Rev. 2007 Apr;87(2):425-56 - PubMed
  52. N Engl J Med. 2000 Mar 30;342(13):913-20 - PubMed
  53. Lancet. 2000 Dec 16;356(9247):2052-8 - PubMed
  54. Europace. 2014 Jan;16(1):101-8 - PubMed
  55. Circulation. 2000 Nov 7;102(19):2385-90 - PubMed
  56. J Clin Invest. 2014 Apr;124(4):1770-80 - PubMed
  57. J Am Coll Cardiol. 2010 Mar 2;55(9):934-47 - PubMed
  58. Circulation. 2012 Jan 17;125(2):381-9 - PubMed
  59. Eur Heart J. 2014 Jul 1;35(25):1642-51 - PubMed
  60. Lancet. 1999 Jan 2;353(9146):9-13 - PubMed
  61. Drugs. 2012 Aug 20;72(12):1617-30 - PubMed
  62. Am J Cardiol. 2002 Jun 1;89(11):1316-9 - PubMed
  63. Br J Pharmacol. 2015 Jun;172(11):2878-91 - PubMed
  64. J Cardiovasc Electrophysiol. 2000 Sep;11(9):990-7 - PubMed
  65. Circulation. 1991 Oct;84(4):1831-51 - PubMed
  66. Lancet. 1997 Mar 8;349(9053):667-74 - PubMed
  67. Lancet. 1996 Jul 6;348(9019):7-12 - PubMed
  68. Stem Cells Dev. 2015 May 1;24(9):1035-52 - PubMed
  69. Circ Arrhythm Electrophysiol. 2017 Feb;10 (2):e004628 - PubMed
  70. J Am Coll Cardiol. 2004 Dec 7;44(11):2117-24 - PubMed
  71. Circ Res. 2000 Nov 10;87(10):903-9 - PubMed
  72. N Engl J Med. 2007 Sep 6;357(10):987-99 - PubMed
  73. Lancet. 1999 Jun 12;353(9169):2001-7 - PubMed
  74. Ann Intern Med. 1989 Oct 1;111(7):549-51 - PubMed
  75. Am J Physiol Heart Circ Physiol. 2012 Jul 15;303(2):H144-55 - PubMed
  76. N Engl J Med. 1999 Sep 16;341(12 ):857-65 - PubMed
  77. Europace. 2017 Mar 1;19(3):465-511 - PubMed
  78. Circulation. 1997 Dec 2;96(11):4027-35 - PubMed
  79. Circulation. 2002 Oct 22;106(17):2194-9 - PubMed
  80. N Engl J Med. 2011 Dec 15;365(24):2268-76 - PubMed
  81. J Mol Cell Cardiol. 2010 Oct;49(4):639-46 - PubMed
  82. Br J Pharmacol. 2015 Aug;172(16):4002-11 - PubMed
  83. J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:15-20 - PubMed
  84. Circ Cardiovasc Qual Outcomes. 2010 Nov;3(6):704-9 - PubMed
  85. Br J Pharmacol. 2008 Aug;154(7):1427-38 - PubMed
  86. Circ Res. 2013 Mar 1;112(5):849-62 - PubMed
  87. J Cardiovasc Pharmacol. 2010 May;55(5):428-37 - PubMed
  88. JAMA. 1993 Dec 1;270(21):2590-7 - PubMed
  89. N Engl J Med. 1992 Jul 23;327(4):227-33 - PubMed
  90. Eur Heart J. 2000 Aug;21(15):1265-73 - PubMed
  91. Physiol Genomics. 2015 Sep;47(9):365-75 - PubMed
  92. J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:183-95 - PubMed
  93. Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479-87 - PubMed

Publication Types

Grant support